J. M. Siller-Matula (1), B. Jilma (2)
(1) Department of Cardiology, Medical University of Vienna, Austria; (2) Department of Clinical Pharmacology, Medical University of Vienna, AustriaDepartment of Clinical PharmacologyMedical University of Vienna, Austria
Published data linking clopidogrel non-responsiveness to adverse ischaemic events lead to the suggestion that the magnitude of platelet inhibition by clopidogrel can be monitored and individually adjusted. This has been tested in randomised clinical trials (ARCTIC, GRAVITAS and TRIGGER-PCI), but despite reducing platelet reactivity, a strategy of therapy adjustment based on platelet function monitoring did not reduce the incidence of cardiac ischaemic events. Several critical issues regarding the design of these trials, which might in part have led to negative results, are discussed in this article.